Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
BACKGROUND
Bevacizumab, a monoclonal antibody (mAb) targeting vascular endothelial growth factor (VEGF), has produced promising results when combined with chemotherapy in the treatment of advanced colorectal cancer (CRC). The aim of the present study was to define the immunological profile of metastatic CRC patients at baseline and following chemotherapy with either irinotecan/5-fluorouracil/leucovorin (IFL) alone or IFL in combination with.bevacizumab (B-IFL).


METHODS
Peripheral blood mononuclear cells (PBMCs) obtained from healthy donors (HD) (n = 20) and patients (n = 40) were tested for T-cell proliferation in the autologous mixed lymphocyte reaction (auto-MLR), and cytokine production following stimulation with anti-CD3 mAb.


RESULTS
PBMCs obtained from CRC patients prior to treatment exhibited lower auto-MLR responses and low production of IL-2, IFN-γ, IL-12 and IL-18 cytokines, whereas IL-4 and IL-10 cytokines were increased as compared to HD (p < 0.001, for all parameters) following in vitro stimulation with anti-CD3 mAb. During treatment, and in particular in week 12 of evaluation, IL-2 (p < 0.001 for both IFL and B-IFL groups), IFN-γ (p < 0.001 for IFL and p = 0.001 for B-IFL), IL-12 (p < 0.001 for both IFL and B-IFL) and IL-18 (p < 0.001 for both IFL and B-IFL) production, as well as auto-MLR responses increased (p < 0.001 for both IFL and B-IFL), whereas IL-4 (p < 0.001 for IFL and p = 0.001 for B-IFL) and IL-10 [p < 0.001 for IFL and p = 0.067 (non-significant) for B-IFL] production decreased over baseline in the two treatment groups, yet their respective values never reached those of HD. Moreover, IL-2, IFN-γ production, and auto-MLR were higher in the B-IFL over the IFL treatment group (p < 0.001, p < 0.04, p < 0.001, respectively).


CONCLUSIONS
Our study demonstrates that the abnormal immune parameters observed in metastatic CRC patients at presentation can substantially improve during treatment with either IFL or B-IFL. The immune parameters examined can provide a sensitive and valuable tool for monitoring immune function in CRC patients, and could be applied as surrogate markers predicting treatment-related outcome.
Tsavaris
Nikolaos
N
Oncology Unit, Department of Pathophysiology, Athens University School of Medicine, Laikon General Hospital, 11527 Athens, Greece. tsavari1@otenet.gr
Voutsas
Ioannis F
IF
Kosmas
Christos
C
Gritzapis
Angelos D
AD
Baxevanis
Constantin N
CN
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006115:Greece; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Cancer Immunol Immunother. 2002 Oct;51(8):440-8
12202905
Expert Opin Biol Ther. 2007 Apr;7(4):509-19
17373902
J Immunol. 1990 Dec 1;145(11):3796-806
2147202
Cancer Immunol Immunother. 1998 Jan;45(5):241-9
9439647
Scand J Immunol. 1997 Feb;45(2):182-92
9042431
Int J Cancer. 1993 Aug 19;55(1):96-101
8344757
Anticancer Agents Med Chem. 2007 Sep;7(5):492-503
17896910
Cancer Chemother Pharmacol. 2005 May;55(5):479-87
15726369
Anticancer Res. 1992 Mar-Apr;12(2):489-94
1533752
Eur J Immunol. 1993 Nov;23(11):3043-9
8223881
Br J Cancer. 1997;76(8):1072-80
9376269
Eur J Cancer. 1996 Nov;32A(12):2142-7
9014758
Drugs. 2007;67(13):1851-67
17722954
Cancer. 1981 Jan 1;47(1):207-14
7459811
Cancer. 1999 Feb 1;85(3):517-9
10091724
Oncol Rep. 2005 Jul;14(1):113-20
15944777
Nat Immun. 1993 Jan-Feb;12(1):41-9
8431663
Ai Zheng. 2002 Jan;21(1):45-9
12500396
J Clin Oncol. 2005 May 20;23(15):3502-8
15908660
Hepatogastroenterology. 1999 Jan-Feb;46(25):220-7
10228796
Expert Opin Biol Ther. 2005 Jul;5(7):997-1005
16018743
Breast Cancer Res Treat. 2003 Jul;80(1):1-13
12889594
Nature. 1988 Jul 21;334(6179):255-8
2456466
J Hepatol. 1999 Aug;31(2):323-31
10453947
J Immunol. 2000 Apr 1;164(7):3902-12
10725753
Immunology. 1997 Apr;90(4):463-9
9176096
Ann N Y Acad Sci. 1996 Oct 31;795:410-2
8958969
Gastroenterology. 1996 Feb;110(2):375-82
8566583
Cancer Immunol Immunother. 1996 Oct;43(2):94-102
8954143
J Chemother. 2007 Apr;19(2):115-22
17434818
Br J Cancer. 2000 Mar;82(5):1009-12
10737381
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Dis Colon Rectum. 1998 Apr;41(4):460-3
9559630
Oncogene. 2007 May 28;26(25):3661-78
17530020
Transpl Immunol. 1997 Mar;5(1):35-8
9106332
J Immunol. 1988 Jun 15;140(12):4245-52
2967332
Ann Oncol. 2006 Sep;17(9):1399-403
16873427
Br J Cancer. 1998 Oct;78(8):1018-23
9792144
J Immunol. 1987 Jun 1;138(11):3688-94
2953788